Omadacycline Injection — Competitive Intelligence Brief

Omadacycline Injection (Omadacycline Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Omadacycline Injection (Omadacycline Injection) — Wake Forest University Health Sciences. Omadacycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the ribosome.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Omadacycline Injection TARGET	Omadacycline Injection	Wake Forest University Health Sciences	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Usual doses of tigecycline	Usual doses of tigecycline	Air Force Specialized Hospital, Cairo, Egypt	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline Hyclate Enteric-Coated Capsules	Doxycycline Hyclate Enteric-Coated Capsules	The Third Xiangya Hospital of Central South University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Amikacin (Inhalation)	Amikacin (Inhalation)	The University of Queensland	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Minocycline HCl	Minocycline HCl	OraPharma	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
inhaled tobramycin	inhaled tobramycin	Seattle Children's Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
DoxyPEP	DoxyPEP	Chinese University of Hong Kong	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class